Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0000950170-23-014910
Filing Date
2023-04-26
Accepted
2023-04-26 17:29:43
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFA14A 2023_ovid_proxy_notice__.htm DEFA14A 30404
2 GRAPHIC img94822598_0.jpg GRAPHIC 683012
3 GRAPHIC img94822598_1.jpg GRAPHIC 568894
  Complete submission text file 0000950170-23-014910.txt   1755738
Mailing Address 441 NINTH AVENUE, 14TH FLOOR NEW YORK NY 10001
Business Address 441 NINTH AVENUE, 14TH FLOOR NEW YORK NY 10001 212-776-4381
Ovid Therapeutics Inc. (Filer) CIK: 0001636651 (see all company filings)

EIN.: 465270895 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-38085 | Film No.: 23850975
SIC: 2834 Pharmaceutical Preparations